Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route
Table 1
Short-term (30-day) mortality plus nonfatal acute myocardial infarction with glycoprotein (GP) IIb/IIIa inhibitor’s administration.
Study name
Study type
Primary end-point
Odds ratio
95% CI
Upstream versus downstream
1.0
0.8–1.2
ACUITY
RCT
30-day death
0.9
0.6–1.2
CLOTILDA
RCT
30-day death
0.7
0.1–4.0
EARLY ACS
RCT
30-day death
1.1
8.9–1.4
ELISA
RCT
30-day death
0.6
0.1–2.6
EARLY pilot
RCT
30-day death
5.2
0.2–109
Liu et al.
RCT
30-day death
3.0
0.1–76
ELISA 2
RCT
30-day death
1.0
0.1–16
Small molecules versus abciximab
0.9
0.8–1.2
Danzi et al.
RCT
30-day ALL+NFami
2.0
0.1–75
Ernst et al.
RCT
30-day ALL+NFami
0.8
0.1–8.0
EVA-AMI
RCT
30-day ALL+NFami
1.0
0.5–5.0
MULTISTRATEGY
RCT
30-day ALL+NFami
0.6
0.2–2.0
FATA
RCT
30-day ALL+NFami
2.0
0.6–8.0
Raveedran et al.
R
30-day ALL+NFami
0.7
0.3–3.0
Midei et al.
R
30-day ALL+NFami
2.0
0.6–7.0
Lachance et al.
R
30-day ALL+NFami
1.5
0.4–7.0
Gurm et al.
R
30-day ALL+NFami
0.8
0.6–1.5
Modified from [2, 4]. CI: confidence intervals; RCT: randomised clinical trial; R: registry; NFami: non fatal acute myocardial infarction. Note that odds ratios and CI were rounded off. There was no significant advantage comparing administration modalities or type of GP IIb/IIIa antagonist (comparison confined to small molecules versus abciximab).
